We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

168 hedge funds and large institutions have $1.65B invested in Celldex Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 52 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more call options, than puts

Call options by funds: $72.7M | Put options by funds: $39.3M

23% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 52

6.88% more ownership

Funds ownership: 98.77% → 105.65% (+6.9%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

6% less capital invested

Capital invested by funds: $1.75B → $1.65B (-$104M)

7% less funds holding

Funds holding: 180 → 168 (-12)

33% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 30

Holders
168
Holders Change
-12
Holders Change %
-6.67%
% of All Funds
2.65%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
20
Increased
64
Reduced
52
Closed
30
Calls
$72.7M
Puts
$39.3M
Net Calls
+$33.4M
Net Calls Change
-$18.7M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$43M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$34.8M
3
Morgan Stanley
Morgan Stanley
New York
+$22.8M
4
KCM
Kynam Capital Management
New Jersey
+$16.8M
5
TLP
Tri Locum Partners
New York
+$12.3M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$26.8M
2
OM
Opaleye Management
Massachusetts
-$20.7M
3
CAC
Cowen and Company
New York
-$18M
4
FAM
Fred Alger Management
New York
-$11.1M
5
SI
Sofinnova Investments
California
-$10.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
51
D.E. Shaw & Co
New York
$4.16M -$1.68M -52,613 -30%
Millennium Management
52
Millennium Management
New York
$3.67M +$2.17M +68,030 +171%
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$3.5M +$582K +18,213 +22%
RSCM
54
Rock Springs Capital Management
Maryland
$3.31M +$3.11M +97,317 New
MCP
55
Mirador Capital Partners
California
$3.07M +$128K +3,996 +5%
Swiss National Bank
56
Swiss National Bank
Switzerland
$3M +$201K +6,300 +8%
Verition Fund Management
57
Verition Fund Management
Connecticut
$2.97M +$1.07M +33,368 +62%
Jane Street
58
Jane Street
New York
$2.67M +$1.8M +56,209 +253%
Deutsche Bank
59
Deutsche Bank
Germany
$2.55M -$736K -23,039 -24%
TD Asset Management
60
TD Asset Management
Ontario, Canada
$2.52M +$368K +11,500 +18%
PAMP
61
Polar Asset Management Partners
Ontario, Canada
$2.36M +$2.21M +69,200 New
SCM
62
Soleus Capital Management
Connecticut
$2.35M +$2.21M +69,000 New
ACM
63
Altium Capital Management
New York
$2.25M -$1.92M -60,000 -48%
Manulife (Manufacturers Life Insurance)
64
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.19M +$1.29M +40,225 +173%
Citigroup
65
Citigroup
New York
$2.16M -$1.78M -55,529 -47%
BFM
66
Boothbay Fund Management
New York
$2.11M +$531K +16,615 +37%
State of Wisconsin Investment Board
67
State of Wisconsin Investment Board
Wisconsin
$2.1M +$348K +10,900 +21%
Balyasny Asset Management
68
Balyasny Asset Management
Illinois
$2.09M +$1.72M +53,878 +732%
First Trust Advisors
69
First Trust Advisors
Illinois
$1.8M -$1.57M -49,010 -48%
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$1.78M +$76.6K +2,396 +5%
California State Teachers Retirement System (CalSTRS)
71
California State Teachers Retirement System (CalSTRS)
California
$1.75M -$160K -5,000 -9%
Principal Financial Group
72
Principal Financial Group
Iowa
$1.45M -$483K -15,114 -26%
AllianceBernstein
73
AllianceBernstein
Tennessee
$1.4M +$3.2K +100 +0.2%
Walleye Capital
74
Walleye Capital
New York
$1.27M +$740K +23,154 +163%
Allianz Asset Management
75
Allianz Asset Management
Germany
$1.23M – – –
1 2
3
4 5

CLDX Hedge Fund Activity: Q1 2022 in Review

168 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2022, worth a combined $1.65B — down 5.9% from $1.75B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of CLDX and 20 opened new positions — a net loss of 10 holders — while 52 trimmed existing stakes and 64 added.

The largest buyer was Wellington Management Group, adding an estimated $43M. The largest seller was RTW Investments, cutting an estimated $26.8M.

  • 168 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2022, down from 180 in Q4 2021.
  • Funds reported $1.65B of Celldex Therapeutics stock for Q1 2022, down 5.9% quarter-over-quarter.
  • 20 funds opened new Celldex Therapeutics positions in Q1 2022 and 30 closed out, a net change of -10 holders.
  • The largest Celldex Therapeutics buyer in Q1 2022 was Wellington Management Group, an estimated $43M added.
  • The largest Celldex Therapeutics seller in Q1 2022 was RTW Investments, an estimated $26.8M sold.

Based on aggregated 13F filings for Q1 2022.